Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonists
作者:Aliaa Abdelrahman、Swapnil G. Yerande、Vigneshwaran Namasivayam、Tim A. Klapschinski、Mohamad Wessam Alnouri、Ali El-Tayeb、Christa E. Müller
DOI:10.1016/j.ejmech.2019.111879
日期:2020.1
obtain A1 and A3 AR antagonists including dual-target compounds. Selective A1 antagonists with (sub)nanomolar potency were produced, e.g. 11 and 13. These compounds showed species differences being significantly more potent at the rat as compared to the human A1 AR, and were characterized as inverse agonists. Several potent and selective A3 AR antagonists, e.g. 7, 8, 17 and 22 (Ki values of 5-9 nM at
腺苷通过四个不同的G蛋白偶联受体(称为A1,A2A,A2B和A3腺苷受体(ARs))充当强大的信号分子。A2A和A2B ARs是Gs偶联的,而A1和A3 ARs通过Gi蛋白抑制cAMP的产生。A1和A3 ARs的拮抗剂可用于治疗(神经)炎性疾病,包括急性肾损伤和肾衰竭,肺部疾病和阿尔茨海默氏病。在本研究中,我们通过在N2和C5处引入取代基来获得包括双重靶标化合物的A1和A3 AR拮抗剂,从而优化了通用的2-氨基-4-苯基噻唑支架。产生了具有(亚)纳摩尔效价的选择性A1拮抗剂,例如11和13。这些化合物显示,与人的A1 AR相比,物种差异在大鼠处的效价明显更高,并且被表征为反向激动剂。制备了几种有效的和选择性的A3 AR拮抗剂,例如7、8、17和22(人A3 AR的Ki值为5-9 nM),它们在大鼠直系同源物上的效力要低得多。此外,开发了双重A1 / A3拮抗剂(10、18),显示Ki值在8到42